Bofor Laser Secures Tens of Millions in Series B+ Financing to Lead China's Aesthetic Photonics Equipment Global Expansion

VCBeat has learned that Suzhou BVLASER Technology Co., Ltd. (“BVLASER”) recently announced the completion of its tens-of-millions-yuan Series B+ financing round, exclusively invested by Med-Fine Capital Health Fund. The proceeds will be primarily used to expand production capacity, continue global market expansion, enhance brand image, and drive innovation and iteration of self-developed products.

BVLASER is dedicated to the research and development, manufacturing, and sales of mid-to-high-end medical aesthetic optoelectronic devices. The company boasts over 10 core products and more than 100 intellectual property certificates, and is recognized as a National High-Tech Enterprise. Currently, its products have been exported to more than 70 countries and regions. Driven by impressive market expansion speed and unique product innovation advantages, the company has experienced rapid business growth, achieving a year-on-year performance increase of over 100% compared to 2023.

Relevant statistical data show that the global market size of medical aesthetic optoelectronic devices was approximately USD 15.4 billion in 2023 and is projected to reach USD 25.9 billion by 2028, with a compound annual growth rate (CAGR) of around 11%. As the global medical aesthetics market continues to expand, particularly with the rapid development of emerging markets, global demand for medical aesthetic optoelectronic devices is steadily rising, providing substantial market opportunities for Chinese manufacturers to export their products overseas.

Jia Yangchun, founder of BVLASER, has dedicated 18 years to the global medical aesthetics market, maintaining a strong presence on the front lines to accurately grasp industry trends and customer needs. Through continuous R&D investment and product innovation, the company achieves rapid and iterative product upgrades that precisely address customer pain points. BVLASER has established an extensive agency sales network worldwide, covering mainstream and emerging markets in North America, South America, Europe, and the Asia-Pacific region.

Jia Yangchun, Founder of BVLASERstated, “We are deeply grateful to Med-Fine Capital for its recognition of our company, and we also extend our sincere appreciation to our early-stage investors—Northern Light Venture Capital, Yansheng Venture Capital, and New Airport City Fund—for their continued support. We will continuously optimize our business model, persist in developing new products and exploring new technologies, uphold the principle of making technology accessible to all humanity, and bring high-quality Chinese products to the global market.””

Zhou Yujian, Managing Partner of Med-Fine Capital“The market for medical aesthetic optoelectronic devices is vast, offering significant room for future growth. Through continuous R&D investment and product innovation, BVLASER has steadily expanded its product portfolio and deepened its presence in overseas markets, demonstrating strong global sales capabilities. The team is highly innovative and resilient. Med-Fine Capital firmly believes in the substantial commercial potential of the global medical aesthetics sector and hopes that BVLASER will continue to innovate, bringing more and better products to the market.”

Med-Fine Health Fund focuses on investments in the pharmaceutical, healthcare, and life sciences sectors, with offices in Shanghai and Beijing. The management team boasts a broad international perspective, deep industry background, extensive sector resources, and professional investment expertise. The firm currently manages multiple RMB and USD-denominated funds. Emphasizing “early-stage value discovery and sector opportunity identification,” the fund targets investment opportunities in biopharmaceuticals, medical devices and diagnostics, digital health, and health tech. To date, it has completed investments in more than 60 pharmaceutical and healthcare companies, including Hanyu Medical, TianGuangShi, ImmuneOnco, Zhenrong Pharma, LinkHealth Therapeutics, Chengyi Biopharma, PhenoGen Biologics, HeartCare Medical, Libang Pharmaceutical, Anrui Biotech, Saifu Pharma, Ansung Tech, Aikemai, and Shuimu Medical.

Guided by the vision of “building a global bridge for healthcare connectivity and shaping the horizon of life and health,” and driven by the mission to “leverage capital to foster innovative development in the healthcare industry,” Med-Fine Capital adheres to the core values of “customer first, talent-driven success, quality leadership, and rewarding trust.” Upholding the principles of “specialized expertise, value discovery, risk control, and growth empowerment,” and integrating “decentralized investment” with “systematic operations,” Med-Fine Capital is committed to becoming an open, platform-based, highly competitive, and widely renowned international professional investment institution.